Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
16.09
Dollar change
-0.41
Percentage change
-2.48
%
Index- P/E- EPS (ttm)-0.69 Insider Own2.93% Shs Outstand80.44M Perf Week0.88%
Market Cap1.29B Forward P/E- EPS next Y-0.04 Insider Trans4.37% Shs Float78.08M Perf Month-6.78%
Income-54.59M PEG- EPS next Q-0.06 Inst Own61.45% Short Float8.19% Perf Quarter-21.40%
Sales0.00M P/S- EPS this Y-181.48% Inst Trans43.43% Short Ratio12.13 Perf Half Y-5.02%
Book/sh3.10 P/B5.19 EPS next Y82.89% ROA-19.23% Short Interest6.40M Perf Year-19.79%
Cash/sh3.38 P/C4.76 EPS next 5Y- ROE-22.76% 52W Range11.83 - 23.81 Perf YTD-19.06%
Dividend Est.- P/FCF- EPS past 5Y19.36% ROI-18.23% 52W High-32.42% Beta0.41
Dividend TTM- Quick Ratio33.33 Sales past 5Y-39.77% Gross Margin-110.38% 52W Low36.01% ATR (14)0.84
Dividend Ex-Date- Current Ratio33.33 EPS Y/Y TTM35.45% Oper. Margin0.00% RSI (14)46.85 Volatility4.88% 5.21%
Employees79 Debt/Eq0.21 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price33.14
Option/ShortYes / Yes LT Debt/Eq0.20 EPS Q/Q-27.40% Payout- Rel Volume0.59 Prev Close16.50
Sales Surprise- EPS Surprise33.33% Sales Q/Q-100.00% EarningsFeb 29 BMO Avg Volume527.26K Price16.09
SMA20-1.54% SMA50-5.09% SMA200-7.51% Trades Volume309,338 Change-2.48%
Date Action Analyst Rating Change Price Target Change
May-22-23Resumed Jefferies Buy $35 → $38
Sep-19-22Resumed Wedbush Outperform $27
Aug-26-22Initiated Piper Sandler Overweight $31
Sep-13-21Initiated H.C. Wainwright Buy $25
Aug-25-20Initiated Jefferies Buy $17
Aug-10-20Initiated Canaccord Genuity Buy $17
Apr-18-19Initiated BTIG Research Buy $17
Mar-04-24 02:00AM
Mar-01-24 09:03AM
08:45AM
Feb-29-24 06:36AM
02:00AM
02:00AM Loading…
Feb-15-24 02:00AM
Feb-01-24 02:00AM
Jan-03-24 02:00AM
Jan-02-24 02:00AM
Dec-30-23 06:50AM
Nov-23-23 09:55AM
Nov-17-23 02:00AM
Nov-14-23 09:09AM
Nov-08-23 02:00AM
Nov-07-23 09:55AM
10:33AM Loading…
Nov-05-23 10:33AM
Nov-04-23 05:02AM
Nov-02-23 08:03AM
03:04AM
Oct-23-23 04:57AM
Oct-19-23 02:00AM
Oct-11-23 09:55AM
Oct-06-23 02:00AM
Oct-04-23 09:35AM
Oct-03-23 02:00AM
Sep-26-23 12:17PM
Sep-11-23 02:00AM
Sep-06-23 02:00AM
Aug-31-23 10:16PM
02:00AM
07:42AM Loading…
Aug-08-23 07:42AM
06:41AM
Aug-03-23 02:00AM
Jul-26-23 02:00AM
Jul-20-23 02:00AM
Jun-28-23 02:00AM
Jun-27-23 02:00AM
May-24-23 02:00AM
May-09-23 02:00AM
May-02-23 02:00AM
Apr-25-23 02:00AM
Apr-11-23 06:05AM
Apr-10-23 02:00AM
Apr-04-23 06:15PM
Mar-30-23 05:22PM
Mar-28-23 06:15PM
Mar-22-23 06:00PM
Mar-15-23 11:44AM
Mar-14-23 06:15PM
Mar-09-23 01:59AM
Mar-08-23 02:50PM
07:56AM
Mar-07-23 02:00AM
Mar-01-23 06:00PM
05:57AM
Feb-23-23 06:00PM
Feb-21-23 02:00AM
Feb-15-23 11:49AM
Feb-14-23 06:00PM
Feb-08-23 06:00PM
Feb-02-23 06:00PM
Jan-23-23 06:15PM
Jan-17-23 06:15PM
Jan-10-23 06:15PM
Jan-03-23 05:40AM
Jan-02-23 07:22AM
Dec-30-22 06:25PM
09:03AM
Dec-28-22 11:58PM
Dec-22-22 08:50AM
06:00AM
Dec-20-22 04:06PM
02:02PM
08:43AM
08:18AM
08:14AM
02:00AM
Dec-19-22 04:01PM
Dec-06-22 08:50AM
Dec-05-22 12:00PM
Dec-02-22 09:55AM
Nov-15-22 09:55AM
08:50AM
Nov-09-22 02:00AM
Nov-06-22 07:00PM
Nov-02-22 09:48AM
03:00AM
Oct-26-22 02:00AM
Oct-17-22 04:44PM
02:00AM
Oct-14-22 02:00AM
Sep-22-22 06:51AM
Sep-20-22 12:24PM
Aug-29-22 02:48PM
02:00AM
Aug-24-22 02:00AM
Aug-19-22 02:46AM
Aug-15-22 04:05PM
Aug-14-22 11:32AM
Aug-10-22 08:22PM
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rickard Kathleen A.Chief Medical OfficerFeb 05 '24Sale2.2236,24880,5032,731,624Feb 05 06:11 PM
Edwards MartinDirectorNov 20 '23Buy1.8433,73661,973144,800Nov 22 05:09 PM
EBSWORTH DAVID RDirectorNov 06 '23Buy1.98160,000316,080844,643Nov 08 04:15 PM
Rickard Kathleen A.Chief Medical OfficerNov 03 '23Sale1.9258,752112,8042,840,640Nov 03 08:11 PM
Hahn Mark WChief Financial OfficerAug 07 '23Sale2.478,61621,26315,521,248Aug 07 09:17 PM
ZACCARDELLI DAVIDPresident and CEOAug 07 '23Sale2.478,61621,26316,431,800Aug 07 09:17 PM
Rickard Kathleen A.Chief Medical OfficerAug 07 '23Sale2.471,6003,9492,872,528Aug 07 09:19 PM
Poll ClaireGeneral CounselAug 07 '23Sale2.471,5123,7311,907,367Aug 07 09:15 PM
ZACCARDELLI DAVIDPresident and CEOAug 04 '23Sale2.50150,000374,88016,440,416Aug 07 09:17 PM
Hahn Mark WChief Financial OfficerAug 04 '23Sale2.50150,000374,88015,529,864Aug 07 09:17 PM
Rickard Kathleen A.Chief Medical OfficerAug 04 '23Sale2.5027,94469,8382,874,128Aug 07 09:19 PM
Poll ClaireGeneral CounselAug 04 '23Sale2.5026,35265,8591,908,879Aug 07 09:15 PM
Hahn Mark WChief Financial OfficerAug 03 '23Sale2.54117,272297,75415,679,864Aug 07 09:17 PM
ZACCARDELLI DAVIDPresident and CEOAug 03 '23Sale2.54117,272297,75416,590,416Aug 07 09:17 PM
Rickard Kathleen A.Chief Medical OfficerAug 03 '23Sale2.5550,600128,7902,902,072Aug 07 09:19 PM
Poll ClaireGeneral CounselAug 03 '23Sale2.5420,60852,3241,935,231Aug 07 09:15 PM
ZACCARDELLI DAVIDPresident and CEOAug 02 '23Sale2.5973,704191,11416,707,688Aug 03 08:29 PM
Hahn Mark WChief Financial OfficerAug 02 '23Sale2.5973,704191,11415,797,136Aug 03 08:31 PM
Rickard Kathleen A.Chief Medical OfficerAug 02 '23Sale2.5913,72835,5972,952,672Aug 03 08:27 PM
Poll ClaireGeneral CounselAug 02 '23Sale2.5912,94433,5641,955,839Aug 03 08:30 PM
ZACCARDELLI DAVIDPresident and CEOAug 01 '23Sale2.68105,944283,82416,781,392Aug 03 08:29 PM
Hahn Mark WChief Financial OfficerAug 01 '23Sale2.68105,944283,82415,870,840Aug 03 08:31 PM
Rickard Kathleen A.Chief Medical OfficerAug 01 '23Sale2.6819,73652,8732,966,400Aug 03 08:27 PM
Poll ClaireGeneral CounselAug 01 '23Sale2.6818,60849,8511,968,783Aug 03 08:30 PM
ORBIMED ADVISORS LLCDirectorMay 15 '23Sale20.08359,7137,222,4843,777,778May 15 06:07 PM
Gupta RishiDirectorMay 15 '23Sale20.08359,7137,222,4843,777,778May 15 06:06 PM
Gupta RishiDirectorMay 12 '23Sale21.6443,200934,8484,137,491May 15 06:06 PM
ORBIMED ADVISORS LLCDirectorMay 12 '23Sale21.6443,200934,8484,137,491May 15 06:07 PM
ORBIMED ADVISORS LLCDirectorMay 11 '23Sale22.2680,0001,780,8004,180,691May 15 06:07 PM
Gupta RishiDirectorMay 11 '23Sale22.2680,0001,780,8004,180,691May 15 06:06 PM
Rickard Kathleen A.Chief Medical OfficerMay 03 '23Sale2.6528,75276,2422,971,136May 03 07:49 PM
ZACCARDELLI DAVIDPresident and CEOMay 01 '23Sale2.58455,5361,173,41516,887,336May 03 07:46 PM
Hahn Mark WChief Financial OfficerMay 01 '23Sale2.58455,5281,173,39515,976,784May 03 07:48 PM
Poll ClaireGeneral CounselMay 01 '23Sale2.5880,376207,0411,979,063May 03 07:49 PM
Rickard Kathleen A.Chief Medical OfficerMay 01 '23Sale2.5877,424199,4362,999,888May 03 07:49 PM